Exosome Dx will help further Merck's drug development efforts in oncology and other areas using its exosome-based nucleic acid and protein detection technology.
The company developed the instrument using in-licensed technology coupled with its own chemistry and other technology for exosomal protein analysis.
The deal follows a June agreement under which Exosome is developing an exosomal RNA sequencing platform with Takeda.
The partners will develop a biomarker discovery platform based on Exosome Diagnostics' exosomal RNA sequencing technology.
The results support the tests potential to more specifically predict high-risk prostate cancers, and lower the number of unnecessary prostate biopsies.
The company said it would use the funds to support growth in its commercial diagnostics, regulatory, and companion diagnostics divisions.
The firm is also expanding its diagnostics sales force and adding development and regulatory staff ahead of near-term product launches.
The funding coincides with publication of reports from the Extracellular RNA Consortium outlining growth and challenges in exosomal RNA-based diagnostics.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.